# Safety and Efficacy Evaluation of CD19-UCART

> **NCT03229876** · NA · SUSPENDED · sponsor: **Bioray Laboratories** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)
- Non Hodgkin Lymphoma (NHL)

## Interventions

- **BIOLOGICAL:** CD19-UCART

## Key facts

- **NCT ID:** NCT03229876
- **Lead sponsor:** Bioray Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2019-06-01
- **Primary completion:** 2023-12-15
- **Final completion:** 2023-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-07-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229876, "Safety and Efficacy Evaluation of CD19-UCART". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03229876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*